Boston Scientific shook up the cardiovascular world this week with its decision to retire its entire Lotus transcatheter aortic valve replacement (TAVR) platform. That decision translates into job loss for 106 Minnesota-based employees, according to reports from Bring Me the News and MassDevice.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,